March 20, 2020

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.

Enclosed is a Press Release as regards launch of Betamethasone Dipropionate Ointment USP
(Augmented), 0.05%, for which, approval from the U.S. FDA was received earlier.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing

Thanking you,

For LUPIN LIMITED

R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)

Encl.: a/a
Lupin launches Betamethasone Dipropionate Ointment USP (Augmented)

Mumbai, Baltimore, March 20, 2020: Pharma major Lupin Limited (Lupin) announced the launch of Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured at Lupin’s Pithampur (Unit III) facility, India.

Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, is the generic equivalent of Diprolene® Ointment, 0.05%, of Merck Sharp and Dohme Corp. It is a corticosteroïd indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older.

Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, (RLD: Diprolene®) had an annual sales of approximately USD 21 million in the U.S. (IQVIA MAT January 2020).

About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6% of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.  
Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/  
| Facebook: www.facebook.com/LupinWorld/

For further information or queries please contact –

<table>
<thead>
<tr>
<th>Arvind Bothra</th>
<th>Manjira Sharma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Head – Investor Relations and Corporate Communications</td>
<td>General Manager – Corporate Communications</td>
</tr>
<tr>
<td>Email: <a href="mailto:arvindbothra@lupin.com">arvindbothra@lupin.com</a></td>
<td>Email: <a href="mailto:manjirasharma@lupin.com">manjirasharma@lupin.com</a></td>
</tr>
<tr>
<td>Tel: +91 22 6640 8237</td>
<td>Tel: +91 22 6640 2532</td>
</tr>
</tbody>
</table>

*Safe Harbor Statement*  
Diprolene® is a registered trademark of Merck Sharp and Dohme Corp